Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$52.08 -4.1%	$50.39	$21.34 ▼ $58.40	$4.15B	-0.15	1.05 million shs	881,281 shs
AXSM Axsome Therapeutics	$111.70 -0.5%	$106.47	$72.21 ▼ $139.13	$5.50B	0.46	666,539 shs	453,651 shs
JANX Janux Therapeutics	$26.40 -4.9%	$24.60	$22.48 ▼ $71.71	$1.56B	2.86	875,353 shs	908,736 shs
TLX Telix Pharmaceuticals	$16.23 +0.6%	$16.50	$13.61 ▼ $30.36	$5.49B	N/A	28,888 shs	13,127 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+1.36%	+4.48%	-1.93%	+44.38%	+100.63%
AXSM Axsome Therapeutics	+0.83%	+1.36%	+10.47%	+7.45%	+34.03%
JANX Janux Therapeutics	+2.78%	+8.36%	+21.13%	-6.53%	-36.80%
TLX Telix Pharmaceuticals	+3.00%	+0.25%	-3.06%	-3.41%	+1,613,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.6862 of 5 stars	3.5	1.0	0.0	4.7	2.8	0.8	0.0
AXSM Axsome Therapeutics	4.6812 of 5 stars	4.5	1.0	0.0	4.5	2.1	4.2	0.6
JANX Janux Therapeutics	2.0178 of 5 stars	3.5	1.0	0.0	0.0	2.5	2.5	0.0
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	58.41% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	54.28% Upside
JANX Janux Therapeutics	3.08	Buy	$91.89	248.06% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	37.61% Upside

Current Analyst Ratings Breakdown

Latest JANX, TLX, AXSM, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/5/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
AXSM Axsome Therapeutics	$385.69M	14.26	N/A	N/A	$1.18 per share	94.66
JANX Janux Therapeutics	$10.59M	147.51	N/A	N/A	$19.49 per share	1.35
TLX Telix Pharmaceuticals	$516.72M	10.63	$0.12 per share	137.23	$1.12 per share	14.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.61	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	N/A	-9.29%	-8.89%	8/6/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	33.81	N/A	N/A	N/A	N/A	8/20/2025 (Estimated)

Latest JANX, TLX, AXSM, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.95	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	JANX Janux Therapeutics	-$0.50	N/A	N/A	N/A	$0.30 million	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
AXSM Axsome Therapeutics	3.48	2.03	1.96
JANX Janux Therapeutics	N/A	58.47	58.47
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
AXSM Axsome Therapeutics	81.49%
JANX Janux Therapeutics	75.39%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
AXSM Axsome Therapeutics	22.30%
JANX Janux Therapeutics	8.10%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
JANX Janux Therapeutics	30	59.17 million	54.38 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.38 million	N/A	N/A

JANX, TLX, AXSM, and AKRO Headlines

Recent News About These Companies

William Blair Brokers Decrease Earnings Estimates for TLX

July 17 at 3:01 AM | americanbankingnews.com

William Blair Has Negative Outlook of TLX FY2025 Earnings

July 16 at 6:46 AM | marketbeat.com

Missing the first double on this biotech star

July 15 at 9:15 PM | msn.com

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

July 15 at 11:31 AM | msn.com

William Blair Reiterates Outperform Rating for Telix Pharmaceuticals (NASDAQ:TLX)

July 12, 2025 | americanbankingnews.com

Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially ...

July 11, 2025 | insidermonkey.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Should You Sell?

July 10, 2025 | marketbeat.com

Gozellix Receives Permanent HCPCS Code

July 9, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?

July 9, 2025 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from William Blair

July 9, 2025 | marketbeat.com

Telix shares jump 7% on big US news

July 8, 2025 | msn.com

Telix Pharmaceuticals Stock Short Interest Report | NASDAQ:TLX - Benzinga

July 3, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Buy Recommendation

July 3, 2025 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened

July 3, 2025 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at HC Wainwright

July 3, 2025 | marketbeat.com

Up 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'

June 30, 2025 | msn.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What Happened

June 27, 2025 | marketbeat.com

Telix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses

June 25, 2025 | finanznachrichten.de

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?

June 23, 2025 | marketbeat.com

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

June 23, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?

June 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, TLX, AXSM, and AKRO Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$52.08 -2.25 (-4.14%)

Closing price 04:00 PM Eastern

Extended Trading

$52.74 +0.66 (+1.27%)

As of 06:22 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Axsome Therapeutics NASDAQ:AXSM

$111.70 -0.54 (-0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$111.43 -0.27 (-0.25%)

As of 04:09 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Janux Therapeutics NASDAQ:JANX

$26.40 -1.35 (-4.86%)

Closing price 04:00 PM Eastern

Extended Trading

$26.40 +0.01 (+0.02%)

As of 05:45 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Telix Pharmaceuticals NASDAQ:TLX

$16.23 +0.09 (+0.56%)

Closing price 03:59 PM Eastern

Extended Trading

$16.29 +0.06 (+0.38%)

As of 04:52 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time